Summary of Key Points from Conference Call Records Industry Overview - **Industry Focus**: Innovative pharmaceuticals, particularly in the context of China's biopharmaceutical sector and its international expansion - **Market Growth**: The total value of BD (Business Development) transactions for innovative drugs is projected to reach $137.7 billion by 2025, a 1.6 times increase year-on-year, significantly surpassing the electric vehicle sector's $74 billion in the same timeframe [1][2][3] Core Insights and Arguments - **International Expansion**: The innovative drug sector is experiencing explosive growth in international markets, with Q1 2026 BD transactions already reaching $60 billion, accounting for 46% of the total for 2025 [1][2] - **Policy Support**: Biopharmaceuticals have been designated as a new pillar industry by the Chinese government, shifting focus from public welfare to GDP contribution, indicating a supportive policy environment for growth [2][3] - **Performance Expectations**: Companies like Heng Rui Medicine are expected to see over 30% growth in innovative drug revenue by 2026, with significant contributions from key products [1][3] - **Clinical Developments**: Major clinical data releases are anticipated from key conferences such as AACR and ASCO, which could catalyze market movements [1][5] Notable Companies and Their Prospects - **Heng Rui Medicine**: Expected to achieve over 30% growth in innovative drug revenue, with a strong pipeline of 53 products anticipated for approval between 2022 and 2028 [15] - **Kangfang Biopharma**: Key product AK112 is set to release critical clinical data in 2026, which could significantly impact its market position [11][13] - **Baiyi Shenzhou**: Projected profits of $700-800 million in 2026, indicating a rapid profit climb [1][8] - **Xinda Biopharma**: Anticipated to benefit from new product approvals and commercial launches, with a focus on expanding its product pipeline [6][8] Investment Opportunities - **Recommended Stocks**: Key investment targets include Kangfang Biopharma, Xinda Biopharma, Baiyi Shenzhou, and Kelong Biotechnology in the H-share market, and Xintai, Haishike, and Heng Rui Medicine in the A-share market [4][8] - **Undervalued Stocks**: Companies like Hot Scene Biopharma and Yifang Biopharma, which have seen significant price declines, are suggested for bottom-fishing opportunities [4][8] Emerging Trends - **Small RNA Technology**: The small RNA sector is entering a critical phase with breakthroughs in liver-targeted delivery technologies, and several companies are expected to announce significant clinical data in 2026 [18][22] - **Clinical Data Impact**: Recent clinical data from companies like Serapta and Wave Life Sciences highlight the potential and challenges within the small RNA space, influencing market sentiment and investment strategies [20][21] Conclusion - The innovative pharmaceutical sector in China is poised for significant growth driven by international expansion, supportive policies, and strong company performances. Key clinical events and emerging technologies present substantial investment opportunities, particularly in small RNA and innovative drug development.

Group 1: Market Trends and Strategies - The market sentiment has shifted from aggressive to defensive positioning, with funds reallocating towards consumer and financial sectors in search of safety margins amid rising uncertainties [2] - After nine weeks of net outflows, broad-based ETFs saw a slight net inflow of 9.5 billion yuan last week, indicating a potential change in investor sentiment [2] Group 2: Power and Environmental Sector Insights - In the first two months of 2026, thermal power generation volume turned positive year-on-year, and coal prices decreased, suggesting potential profit growth for some thermal power companies [3] - The environmental sector is expected to see stable growth, with a focus on waste incineration power companies and adjustments in water pricing [3] Group 3: Renewable Energy and Energy Security - The ongoing geopolitical tensions have highlighted the importance of energy security, prompting a shift towards local and diversified energy sources, which may accelerate the transition to renewable energy [4] - The demand for renewable energy is expected to increase significantly, potentially leading to a doubling of green certificate prices, enhancing profitability for green power operators [6] Group 4: Real Estate Market Dynamics - The real estate market is showing signs of stabilization, with a notable increase in second-hand housing transactions, while new housing sales have declined [5] - The recovery in the real estate market is expected to be gradual, with a focus on quality property companies and property management firms as investment opportunities [5] Group 5: Company-Specific Performance - Huatai Medical reported a revenue of 2.584 billion yuan and a net profit of 821 million yuan for 2025, reflecting a year-on-year increase of 25.1% and 21.9% respectively, indicating a strong performance [8] - Kangnuo Ya-B announced a significant acquisition by Gilead, which is expected to enhance its platform value and accelerate the commercialization of its products [9] - Yunda Co. achieved a revenue of 29.4 billion yuan in 2025, with a net profit of 340 million yuan, despite facing challenges from low-price orders [10] Group 6: Sector Recommendations - The report recommends investing in undervalued Hong Kong green power operators that are expected to benefit from the linkage between electricity certificates and carbon pricing [6] - Companies with integrated green energy capabilities are highlighted as effective strategies to mitigate carbon cost risks and compliance challenges [6]

证券研究报告 科伦博泰生物-B (6990 HK) 港股通 SKB264 商业化蓄势待发，OptiDC 平 台或多点开花 2026 年 3 月 24 日│中国香港 生物医药 公司公布 25 年报业绩：收入 20.58 亿元（+6.5% yoy），年内亏损 3.82 亿 元（对比 24 年同期 2.67 亿元）。公司 25 年收入稳定增长（其中，2H25 收入持续环比增长，环比+17%），主因：1）SKB264 国内销售持续爬坡（25 年公司商业化合计收入 5.43 亿元，主要贡献品种为 SKB264，但阶段性受 医保调价相关存货调整影响）；2）BD/研发服务相关收入 15.15 亿元。展 望 2026 年，我们看好 SKB264 销售快速爬坡（两大适应症新入医保，其中 EGFRmt NSCLC 3L OS 数据亮眼，叠加销售团队扩容），1L NSCLC(PD-L1 TPS≥1%）等重磅数据或陆续读出。考虑 MSD 海外 III 期临床有望陆续自 26 年底抵达临床终点+SKB571 潜在解锁下一重磅潜力，维持"买入"。 SKB264:看好国内进入医保后放量，海外有望自 26 年底开始报产 2）海外三期数据有望 ...

Investment Rating - The report maintains an "Overweight" rating for the biopharmaceutical and chemical pharmaceutical sectors [6]. Core Insights - The Chinese innovative drug sector is at the beginning of a long cycle, with continuous global output of high-quality assets from Chinese companies. The potential of these assets is not fully reflected in A/H share pricing, leading to a recommendation for the innovative drug sector [1]. - The number and value of business development (BD) deals in the Chinese innovative drug industry have reached record highs in 2023, with 45 BD deals completed (+73% year-on-year) and a total disclosed amount of $57.5 billion (+135% year-on-year) [2]. - The report highlights a significant valuation gap between A/H shares and US stocks for similar innovative drug assets, indicating that A/H shares are systematically undervalued [4]. Summary by Sections Business Development Trends - The report notes that the Chinese innovative drug sector has achieved a global market share of approximately 20% in the number of BD projects and around 75% in the disclosed amount [2]. - There is a high predictability of continued growth in BD activities, driven by increasing interest from multinational corporations (MNCs) and private equity (PE) firms in Chinese assets [2]. Cash Flow Contributions - The report emphasizes that platform companies in China are expected to generate sustainable cash flows through ongoing BD activities, which have not been adequately valued in the market [3]. - It is projected that significant BD deals (with upfront payments exceeding $500 million) will contribute to continuous cash flow growth for companies like Heng Rui Medicine, Shiyao Group, and others [3]. Valuation Comparisons - The report compares the valuations of similar assets in A/H shares and US markets, revealing that Chinese innovative drug companies are undervalued relative to their US counterparts [4][19]. - Specific case studies illustrate the valuation discrepancies, such as between MSD and Kelun Biotech, and Insmed and Haizhi Pharmaceutical, highlighting the potential for significant upside in A/H share valuations [19][22]. Investment Recommendations - The report recommends focusing on large pharmaceutical and biopharmaceutical companies with sustained BD capabilities, including Heng Rui Medicine, Shiyao Group, and others [5]. - Companies that have completed large BD deals are expected to benefit from ongoing milestone cash flows, with specific recommendations for companies like Kelun Biotech and Rongchang Biopharmaceutical [5]. Target Prices and Market Outlook - Target prices for recommended stocks are provided, with specific price targets for companies such as Shiyao Group at HKD 19.25 and Heng Rui Medicine at HKD 98.43, indicating a bullish outlook for these stocks [26].

Summary of Key Points from Conference Call Records Industry Overview - The focus for pharmaceutical investments in 2026 is on ADC (Antibody-Drug Conjugates), second-generation IO (Immuno-Oncology), small nucleic acids, and weight loss sectors, with the CRO (Contract Research Organization) industry expected to see a demand turning point as global investment and financing recover [1][2]. Core Insights and Arguments Company-Specific Developments - **Kanglongda (科伦博泰)**: SKB264 is being advanced overseas by Merck with 17 Phase III clinical trials, with key data expected in 2026 for lung cancer and breast cancer indications [1][4]. - **Shiyao Group (石药集团)**: Achieved significant business development (BD) progress with AstraZeneca on the GLP-1 platform, exceeding market expectations. The EGFR ADC has received three FDA fast track designations, and multiple small nucleic acid pipelines are expected to enter IND in 2026 [1][4]. - **Kangfang Biotech (康方生物)**: Has 14 Phase III clinical trials globally for AK112, with key data readouts expected in H2 2026 for lung cancer and cholangiocarcinoma [1][4]. - **Hengrui Medicine (恒瑞医药)**: Entering a positive performance cycle with expectations of 10 innovative drug approvals in 2026 and over 20 Phase III clinical data readouts [1][8]. - **Innovent Biologics (信达生物)**: Anticipates significant revenue growth in 2026, primarily from the high-volume launch of Ma Shidu peptide and ongoing commercialization of new molecules [1][9]. - **Rongchang Biotech (荣昌生物)**: Expects to achieve breakeven in 2026, with significant overseas clinical progress for RC118 in collaboration with AbbVie [1][10]. Investment Themes - **Innovation Line**: Optimism for innovative drug investments in 2026, driven by improved global liquidity and supportive domestic policies. Key areas include ADC, second-generation IO, small nucleic acids, and weight loss therapies [2]. - **Global Expansion**: Increased market attention on companies going global, with the Chinese pharmaceutical industry gradually gaining global competitiveness. However, challenges remain in the long-term process of internationalization [2]. - **Marginal Changes**: Policy support and improvements are expected to be significant trading logic in 2026, with a focus on CRO industry recovery and opportunities arising from supply-demand improvements [2]. Clinical and Regulatory Milestones - **Clinical Trials**: Multiple companies are expected to report critical clinical data in 2026, including early data from various ADC and IO projects, with significant implications for their market positions [5][6][11]. - **Regulatory Approvals**: Companies like Hengrui and Shiyao are on track for numerous drug approvals and submissions, indicating a robust pipeline and regulatory strategy [8][4]. Other Important Insights - **Market Dynamics**: The CRO sector is highlighted as a key area for recovery, with companies like WuXi AppTec and Tigermed expected to benefit from renewed global demand [2]. - **Emerging Technologies**: The focus on innovative drug development, particularly in the context of ADC and IO, reflects a broader trend towards precision medicine and targeted therapies [1][2]. This summary encapsulates the critical developments and insights from the conference call records, providing a comprehensive overview of the pharmaceutical industry's landscape and specific company trajectories for 2026.

Core Insights - The Chinese innovative pharmaceutical industry is transitioning from "catching up" to "keeping pace" and even "leading" on a global scale, with a significant increase in business development (BD) transactions indicating enhanced international competitiveness [2][11][12] - The trend of BD transactions is accelerating, with record-breaking transaction sizes and optimized structures, marking a shift from single product licensing to platform-based and systematic collaborations [2][11] - The demand for Chinese innovative assets from global pharmaceutical companies is increasing due to challenges such as patent cliffs and declining R&D returns, creating a supportive environment for the high activity in the BD market [12] Recent Market Performance and BD Transaction Analysis - In January 2026, the pharmaceutical and biotechnology sector outperformed the CSI 300 index, rising by 2.97% compared to the index's 1.65% increase, reflecting a revaluation of the innovative drug industry [14] - A notable BD transaction occurred on January 30, 2026, when CSPC Pharmaceutical Group signed a collaboration and licensing agreement with AstraZeneca, involving a $1.2 billion upfront payment and potential milestone payments totaling up to $35 billion for development and $138 billion for sales [15][16] - This transaction exemplifies a platform-based approach, including not only the clinical-stage product SYH2082 but also three preclinical products and four new collaboration projects leveraging CSPC's proprietary technologies [15][16] Potential BD Target Value Identification and Screening Logic - Identifying potential BD targets should focus on differentiated technological barriers, such as the proprietary ADC technology of Kelun-Biotech, which has shown promising clinical data for international licensing [19] - The quality of proof of concept (POC) data is crucial, as seen with Innovent Biologics' IBI363, which has demonstrated efficacy in challenging tumor types, indicating significant commercial potential [19][20] - Global clinical demand and competitive landscape for indications are important, with companies like 3SBio and Diligent Pharma showing strong potential in weight management and oncology, respectively, enhancing their market entry opportunities [20] Conclusion - The Chinese innovative pharmaceutical industry is entering an "Innovation 3.0 era," characterized by a shift from single product licensing to systematic technology platform outputs and deep strategic alliances [21] - The current high activity in BD transactions reflects the industry's strengthening capabilities and serves as a catalyst for value reassessment, positioning companies with technological advantages and high-quality clinical data for significant roles in the global pharmaceutical landscape [21]

Core Viewpoint - The Chinese innovative pharmaceutical sector is entering a golden development period, presenting a once-in-a-century investment opportunity due to unmet global medical needs and significant advancements in the industry [4][9]. Group 1: Market Growth and Trends - In 2025, the total value of out-licensing (BD) transactions for Chinese innovative drugs reached $135.7 billion, a significant increase from $51.9 billion in 2024, with upfront payments rising to $7 billion from $4.1 billion [4][9]. - In January 2026 alone, the transaction volume reached $30 billion, with upfront payments of $3 billion, indicating a strong start to the year [4][9]. - The proportion of external procurement pipelines from China for multinational pharmaceutical companies surged from 10% in 2020 to 42% in 2025, highlighting China's growing importance in the global pharmaceutical landscape [4][9]. Group 2: Clinical Milestones and Innovations - 2026 is identified as a critical year for validating major drugs, with several key clinical milestones expected to emerge, potentially leading to a re-evaluation of industry value [5][9]. - Notable clinical trials include Kangfang Biotech's AK112 for non-small cell lung cancer, which is anticipated to redefine first-line treatment standards [5][9]. - The ADC sector is also poised for significant developments, with Kelong Botai's SKB264 and Baili Tianheng's BL-B01D1 expected to release important phase III clinical data [5][9]. Group 3: Impact on Related Industries - The CXO (Contract Research Organization) sector, closely tied to innovative pharmaceuticals, is expected to benefit from the technological advancements in drug development, leading to a recovery in industry sentiment [5][10]. - Companies within the "WuXi" ecosystem, such as WuXi Biologics and WuXi AppTec, are experiencing a resurgence in orders and performance, reaching historical highs despite previous unfavorable U.S. policies [10].

Summary of Conference Call Notes Industry Overview - The conference call primarily focuses on the pharmaceutical industry, specifically highlighting key players such as Merck and Takeda. Key Points from Merck - Merck emphasizes the continuity of its product pipeline, with SKB264 identified as a next-generation core product [1] - The report highlights the performance focus, aiming for multiple blockbuster products to be launched, which is expected to completely offset the patent cliff of Keytruda (K drug) [1] - SKB264 is anticipated to have several overseas Phase III clinical trial data disclosures starting in 2027, with CNPV expected to significantly accelerate the commercialization approval process [1] Key Points from Takeda - Takeda introduces several core products: - Oveporexton (TAK-861) for Type 1 Narcolepsy (NT1) is expected to receive approval in H2 2026 [1] - Rusfertide (TAK-121) for Polycythemia Vera (PV) is also projected to be approved in H2 2026 [1] - Zasocitinib (TAK-279) for psoriasis is anticipated to gain approval in H1 2027 [1] Additional Important Information - The information presented is a summary of publicly available data from JPM and does not constitute specific investment advice [1]

Core Insights - The biopharmaceutical industry is at a pivotal moment as it transitions from the "14th Five-Year Plan" to the "15th Five-Year Plan," emphasizing the balance between technological innovation and value-driven growth [1] - The recent surge in the innovative drug sector, with the Shanghai Composite Index achieving a 14-day winning streak and the Hong Kong innovative drug index rising by an average of 12% over three days, indicates strong market support for innovative pharmaceuticals [4] - The Chinese government has reinforced its commitment to the innovative drug sector through policies like "Full Chain Support for Innovative Drug Development," which is expected to create significant industry opportunities [4] Industry Growth Drivers - Innovative drugs are recognized as a critical new productive force, comparable in priority to AI and other emerging technologies, with substantial government backing [4] - In 2025, China signed over 150 new business development (BD) agreements in the innovative drug sector, totaling more than $130 billion, a 150% increase from 2024, with upfront payments reaching $7 billion [5] - The anticipated "milestone" rewards from these agreements could exceed $30 billion in the next 3-5 years, fostering the growth of China's innovative drug market despite inherent development risks [5] Market Dynamics - The global biopharmaceutical development landscape is revitalizing due to expiring drug patents and a favorable interest rate environment, with major pharmaceutical companies increasing their R&D investments [6] - The emergence of blockbuster innovative drugs in China, such as AK112 and SKB264, showcases the potential for significant sales in the global market, with some products challenging established leaders [6][7] - The international geopolitical climate is expected to enhance China's economic prospects, leading to increased capital inflows into A-shares and Hong Kong stocks, signaling the onset of a major bull market [7] Future Outlook - The period between 2026 and 2027 is anticipated to yield significant clinical breakthroughs in innovative drugs, potentially leading to substantial stock price revaluations [7] - The next 20 years are projected to be a prosperous era for China, with substantial returns expected for those following technological innovations in the biopharmaceutical sector [8]

Summary of Key Points from the Conference Call Industry Overview - The biopharmaceutical industry is experiencing significant growth, particularly in the CXO and chemical pharmaceutical sectors, with a notable increase in fund concentration in these areas [1][2] - The demand in the diagnostic and treatment sectors remains stable, and the medical insurance fund balance has significantly improved, indicating effective cost control measures [2][5] - The release of the first commercial insurance innovative drug directory in December 2025 has introduced new payment increments for the pharmaceutical industry [2][5] Financial Performance - In the first three quarters of 2025, the license-out transaction amount reached $92 billion, more than doubling year-on-year, indicating strong international recognition of domestic innovative drugs [2][6] - The IPO market in Hong Kong has rebounded, leading to increased investment activity in the primary market, with multiple pharmaceutical companies going public [2][6] Key Focus Areas for 2026 - The industry is expected to focus on innovative therapies, particularly IO (immune-oncology) bispecific antibodies and GLP-1 (glucagon-like peptide-1) drugs [1][4] - Notable advancements in the IO bispecific antibody field include the rapid development of Kangfang Biotech's PD-1/VEGF bispecific antibody AK112, with several key clinical data updates anticipated in 2026 [1][4][8] - Emerging technologies such as small nucleic acids and in vivo CAR-T are expected to show initial progress [4] GLP-1 Drug Market - The GLP-1 drug market shows immense potential, with Semaglutide leading in sales and Tirzepatide expected to become a new "blockbuster" [3][13] - There is a focus on new directions such as oral long-acting formulations and weight loss/muscle gain applications, with new targets like Amylin being explored [3][13][14] Investment Opportunities - The trend of innovative drugs going overseas is beneficial for industry chain enterprises, including major players like WuXi AppTec and WuXi Biologics, as well as CRO companies like InnoStar and Mediso [3][16] - The life sciences sector, including companies like BPS and Haoyuan, is also worth attention due to strong demand and performance certainty [16] Future Trends - The combination of IO and ADC (antibody-drug conjugates) is seen as a necessary direction for future development, with several companies already initiating clinical trials in this area [10][12] - The dual antibody drugs in the colorectal cancer field are becoming important assets for global pharmaceutical companies, indicating strong competitive potential for domestic products [9] Conclusion - The biopharmaceutical industry is poised for growth driven by innovation, with significant opportunities in both domestic and international markets. The focus on emerging technologies and the successful launch of innovative drugs will likely shape the industry's future landscape [1][4][16]